Literature DB >> 32629001

Chronic stimulation of the sigma-1 receptor ameliorates ventricular ionic and structural remodeling in a rodent model of depression.

Xiuhuan Chen1, Cui Zhang1, Yan Guo1, Xin Liu1, Tianxin Ye1, Yuhong Fo1, Chuan Qu1, Jinjun Liang1, Shaobo Shi1, Bo Yang2.   

Abstract

AIM: The purpose of the study was to investigate what effects the sigma-1 receptor (S1R) could exert on the cardiac myocyte ion channels in a rodent model of depression and to explore the underlying mechanisms since depression is an independent risk factor for cardiovascular diseases including ventricular arrhythmias (VAs).
MATERIALS AND METHODS: To establish the depression model in rats, chronic mild unpredictable stress (CMUS) for 28 days was used. The S1R agonist fluvoxamine was injected intraperitoneally from the second week to the last week for 21 days in total, and the effects were evaluated by patch clamp, western blot analysis, and Masson staining. KEY
FINDINGS: We demonstrated that depression was improved after treatment with fluvoxamine. In addition, the prolongation of the corrected QT (QTc) interval under CMUS that increased vulnerability to VAs was significantly attenuated by stimulation of S1R due to the decreased amplitude of L-type calcium current (ICa-L) and the restoration of reduced transient outward potassium current (Ito) resulting from CMUS induction. The S1R also decelerated Ito inactivation and accelerated Ito recovery by activating Ca2+/calmodulin-dependent kinase II. Moreover, the stimulation of S1R ameliorated the structural remodeling as the substrate for maintenance of VAs. All these effects were abolished by the administration of S1R antagonist BD1047, which verified the roles for S1R. SIGNIFICANCE: Activation of S1R could decrease the vulnerability to VAs by inhibiting ICa-L and restoring Ito, in addition to ameliorating the CMUS-induced depressive symptoms and structural remodeling.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Depression; Ionic remodeling; Sigma-1 receptor; Structural remodeling; Ventricular arrhythmia

Year:  2020        PMID: 32629001     DOI: 10.1016/j.lfs.2020.118047

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Sigma-1 Receptor Alleviates Airway Inflammation and Airway Remodeling Through AMPK/CXCR4 Signal Pathway.

Authors:  Te Jiang; Di Zhao; Zhiyuan Zheng; Zhankui Li
Journal:  Inflammation       Date:  2022-01-14       Impact factor: 4.092

2.  Pinocembrin Decreases Atrial Fibrillation Susceptibility in a Rodent Model of Depression.

Authors:  Qian Ran; Xiaoli Chen; Cui Zhang; Weiguo Wan; Tianxin Ye; Yazhou Sun; Xin Zhao; Shaobo Shi; Bo Yang; Qingyan Zhao
Journal:  Front Cardiovasc Med       Date:  2022-05-20

Review 3.  Emerging Benefits: Pathophysiological Functions and Target Drugs of the Sigma-1 Receptor in Neurodegenerative Diseases.

Authors:  Ning-Hua Wu; Yu Ye; Bin-Bin Wan; Yuan-Dong Yu; Chao Liu; Qing-Jie Chen
Journal:  Mol Neurobiol       Date:  2021-08-12       Impact factor: 5.590

4.  Pinocembrin ameliorates post-infarct heart failure through activation of Nrf2/HO-1 signaling pathway.

Authors:  Xiuhuan Chen; Weiguo Wan; Yan Guo; Tianxin Ye; Yuhong Fo; Yazhou Sun; Chuan Qu; Bo Yang; Cui Zhang
Journal:  Mol Med       Date:  2021-09-06       Impact factor: 6.354

Review 5.  Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders.

Authors:  Kinga Sałaciak; Karolina Pytka
Journal:  Neurosci Biobehav Rev       Date:  2021-11-01       Impact factor: 8.989

6.  Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-go-go-Related Gene and Cav1.2.

Authors:  Zequn Zheng; Dihui Cai; Yin Fu; Ying Wang; Yongfei Song; Jiangfang Lian
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.